Tirzepatide for managing overweight and obesity

Weight-related comorbidities

The marketing authorisations for semaglutide and tirzepatide give the following examples of weight-related comorbidities, but this list is not exhaustive:

Non-alcoholic fatty liver disease was also included as a baseline characteristic in the NICE technology appraisal economic model for tirzepatide.

NHS England's interim commissioning policy for tirzepatide will outline the cohorts of people who will be prioritised by clinical need, taking into account the conditions listed above. But other important comorbidities, for example, learning disabilities and severe and enduring mental illness may also be considered. When the interim commissioning policy is published, this section will be updated.

Weight-related comorbidities should be managed as soon as they are identified, do not wait until the person has lost weight to do this.